Primary hepatocyte model systems remain the “gold standard” for in vitro studies to assess human metabolism and induction of metabolism. However, the use of primary human hepatocytes (PHH) in screening applications is limited by hepatocyte availability, donor variability, high costs, and a relative short lifespan (=10 days) in culture using standard methodologies (i.e. sandwich cultures). The use of HepaRG™ Cells in hepatic screening applications may solve these limitations without sacrificing critical mature hepatocyte phenotypes such as drug metabolizing enzymes, transport proteins, and functional xenobiotic sensing pathways (CAR, PXR, AhR).
During this webinar, we will demonstrate the utility and reproducibility of differentiated, cryopreserved HepaRG™ Cells in hepatic screening applications. We will show data which demonstrate that cryopreserved HepaRG™ Cells are metabolically competent and maintain functional xenobiotic sensing pathways similar to those exhibited in PHH cultures. Finally, we will show the utility of cryopreserved HepaRG™ Cells in the evaluation of intrinsic and metabolically-activated toxicity.